This open-label, dose-escalation study assessed the maximum tolerated dose (MTD) of the new antifungal micafungin in patients undergoing haematopoietic stem cell transplantation (HSCT). Participants received 3, 4, 6 or 8 mg/kg/day micafungin intravenously from 7 days to a maximum of 28 days or until neutropaenia resolved. The MTD was defined as the highest dose not causing the same Grade 3 or 4 adverse event in three or more patients. All 36 participants received X8 days treatment for a median of 18 days (range: 8-28); 1 patient withdrew consent and a further 11 discontinued to receive another systemic antifungal agent for a suspected infection. No case of confirmed invasive fungal infection occurred. Adverse events were those expected for patients undergoing HSCT and showed no evidence of dose-related toxicity. Criteria for MTD were not met; no patient had a Grade 3 or 4 adverse event considered causally related to micafungin. Thus, the MTD of micafungin can be inferred to be 8 mg/kg/day or higher.
Introduction
Invasive or systemic fungal infections are a frequent cause of morbidity and mortality in haemato-oncology patients undergoing intensive chemotherapy or haematopoietic stem cell transplantation (HSCT), with prolonged neutropaenia as the most important risk factor. The most common pathogens are Aspergillus and Candida species.
There is great difficulty in diagnosing fungal infections and most patients receive antifungal therapy in a setting of neutropaenic fever that has not responded to broad spectrum antibiotics. 1 The treatment usually consists of intravenous amphotericin B or fluconazole for suspected Candida infections and lipid associative formulations of amphotericin B if there is a dose-escalation required to cover Aspergillus. Sometimes itraconazole is used, and more recently voriconazole has received a product license and has the advantage of both intravenous and oral administration. 2, 3 As diagnosis is difficult, early intervention is critical and so attempts have been made at prophylaxis against fungal infections, particularly in patients who have had previous known problems with Aspergillus. To this end, itraconazole has been used widely. A previously published meta-analysis of 38 trials showed no benefit of prophylaxis seen in invasive aspergillosis or in overall mortality, as the majority of trials utilized agents with no activity against Aspergillus species (fluconazole, ketoconazole). 4 Recently, a metaanalysis with itraconazole shows that it effectively prevents proven invasive fungal infections and also reduces mortality from these infections. 5 Drugs presently available are toxic, which prevents their long-term prophylactic use in high-risk patients undergoing a HSCT.
There is therefore a demand for newer agents with broad spectrums of activity that will be active by themselves or in combination. The echinocandin antifungal drugs are therefore of interest, and caspofungin was recently approved for treatment of invasive aspergillosis refractory to or intolerant of standard antifungal therapy, for invasive candidiasis and for empiric therapy. [6] [7] [8] In a previous Phase I study in adult haemato-oncology patients doses of micafungin up to 3 mg/kg per day (daily fixed doses of 12.5-200 mg) were well tolerated by adult patients, and the maximum tolerated dose (MTD) was not reached. 9 The aim of the present study was to investigate further the MTD of micafungin in allogeneic and autologous HSCT patients for doses up to 8 mg/kg per day.
Patients and methods

Conduct of study
The study protocol and amendments were reviewed and approved by the Ethics Committee of participating institu-tions. The study was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonization for Good Clinical Practice (ICH-GCP) guidelines. Before inclusion into the study, the study was explained to each patient and he or she gave written informed consent.
Patient selection
Adult patients scheduled to undergo HSCT at four centres in the United Kingdom were eligible to take part in the study. Female patients of child-bearing age had to have a negative pregnancy test and be using a reliable form of contraception. Patients with evidence of liver disease (defined as SGOT/AST or SGPT/ALT or total bilirubin 42.5 times the upper limit of normal), renal impairment (serum creatinine 42.0 mg/dl), evidence of a systemic fungal infection or with known hypersensitivity to echinocandin antifungal agents or structurally related compounds were excluded from the study. Before study enrolment all patients gave written, informed consent for their participation. The study was approved by the relevant ethics committees.
Study design
The study had an open-label, sequential dose-escalation design and proceeded to the next dose level only if the safety review panel (consisting of internal and external experts) determined that the previous dose was safe based on the definition of the MTD. At least eight evaluable patients were required to complete each dosage group.
Participants were screened 72 h before the first administration of study drug. If they met the entry criteria they received either 3.0, 4.0, 6.0 or 8.0 mg/kg/day micafungin administered intravenously as a 1-hour infusion. Micafungin was supplied by Astellas Pharma Inc., Tokyo, Japan.
Daily treatment began 2 to 3 days before transplantation and lasted for a minimum of 7 to a maximum of 28 days; treatment was to stop when neutropaenia resolved (X500 cells/ml). Administration of micafungin was to discontinue if the patient experienced an adverse event, which was considered intolerable by either the investigator or patient, or if the patient required another systemic antifungal agent for a suspected infection.
Routine clinical laboratory assessments of haematology and serum biochemistry were performed at baseline (the time of patient screening) and on days 1, 3, 5, 7, 10, 14, 17, 21, 24 and 28 of treatment. Patients were assessed for fungal infection at baseline and on days 3, 5, 7, 14, 21 and 28. Monitoring of adverse events was done on an on-going basis.
Primary objective
The primary objective of this study was to determine the safety profile and the MTD of micafungin administered to patients undergoing HSCT. Adverse events were graded from 1 to 4 (least to most severe) using the Southwest Oncology Group Toxicity Criteria. 10 The MTD was defined as the highest dose administered without the occurrence of a Grade 3 or 4 adverse event considered by the investigator to be at least possibly related to micafungin in at least three different patients in the same dosage group.
Results
Characteristics of study population Thirty-six patients were enrolled in the study and received at least one dose of micafungin. They ranged in age from 19 to 62 years, with a median age of 47.5 years; 13 of the participants were female. Other patient characteristics are shown in Table 1 . The four groups were similar except that the proportion of allogeneic transplants was higher in the 6.0 mg/kg/day group (62.5%) than in the other groups (25.0-30.0%). The most common underlying illnesses were multiple myeloma, acute myeloid leukaemia, chronic myeloid leukaemia and acute lymphoblastic leukaemia.
One patient (in the 3.0 mg/kg/day group) withdrew consent after 22 days in the study, and a further 11 patients were withdrawn because they received another systemic antifungal agent for a suspected infection (after 9-26 days, median 17 days). Invasive fungal infection was not confirmed for any patient.
Dosing and duration
As shown in Table 2 , the median treatment period was similar (16.5-22.5 days) for all dosage groups. The highest dose given was 900 mg (in the 8.0 mg/kg/day group). All patients received micafungin for at least 8 days, thus fulfilling the minimum of 7 days of therapy as stipulated in the study protocol. Half of the patients completed at least 18 days of micafungin therapy.
Maximum tolerated dose
No patient, in the 3.0, 4.0, 6.0 or 8.0 mg/kg dosage group, had a Grade 3 or 4 adverse event that was assessed by the investigator as causally related. Thus, the pre-defined criterion for MTD (i.e. the occurrence of the same, Grade 3 or 4, causally related adverse event in at least three patients in the same dosage group) was not met.
Safety and tolerability
Overall the nature and incidence of adverse events were as expected for patients who had just undergone HSCT (Table 3 ). The most common adverse events, irrespective of causality, were thrombocytopaenia, hypokalaemia, mucositis, anaemia, hyperglycaemia, diarrhoea, fever and nausea. Adverse events that were assessed by the investigator as having at least a possible relationship to micafungin comprised phlebitis (three patients), fever and diarrhoea (two patients each) and injection-site reaction, abdominal pain, asthenia, hypertension, dyspepsia, nausea, vomiting, albuminuria, bilirubinaemia, hypervolaemia, hypercalcaemia, maculopapular rash, rash and pruritus (one patient each). All of these adverse events were rated as mild or moderate in severity.
One hepatic adverse event (a patient with mild bilirubinaemia in the 8.0 mg/kg/day group) was assessed by the investigator as being possibly related to the study drug. The overall incidence of hepatic adverse events, irrespective of causality, was similar across dosage groups and showed no dose trend. There were no marked changes over time in average SGOT, SGPT or gamma-GT values in any dosage group (Table 4) . Average serum bilirubin values increased during the first few days of treatment to a similar extent in all dosage groups.
No adverse event related to kidney function was assessed by investigators as having a relationship to the study drug. The incidence of kidney function adverse events, irrespective of causality, was higher in the 6.0 mg/kg/day group than in the other three dosage groups, and average creatinine and urea values increased over time in this group ( Table 4 ). Five of the eight patients in the 6.0 mg/kg/ day group had increased creatinine and/or urea. Four of the five patients received an allogeneic transplant and were maintained on immunosuppressive therapy with cyclosporine. The remaining patient underwent an autologous transplantation and the post transplantation course was complicated by bacterial sepsis. Rash and pruritus (potential histamine-related adverse events) were assessed by the investigator as causally related for two patients; both were in the 8 mg/kg/day dosage group and were graded as having mild severity. No systemic infusion-related adverse events were reported.
An injection-site reaction was reported for one patient in the 3.0 mg/kg/day group and one in the 4.0 mg/kg/day group, and phlebitis was reported for one patient in the 3.0 mg/kg/day group, two in the 4.0 mg/kg/day group and one in the 6.0 mg/kg/day group. These were mild or moderate in all patients. One of the cases of injection-site reaction and three of the cases of phlebitis were assessed by the investigator as causally related to the study drug.
Discussion
As reliable diagnosis of invasive fungal infections is difficult and early intervention is critical in patients at risk for fungal infections, prophylaxis against fungal infections is desirable. The ideal antifungal agent for prophylaxis would provide protection against a wide range of fungal pathogens with minimal toxicity. In order to achieve effective prophylaxis with an acceptable safety profile, it is crucial to determine doses associated with a minimal risk of toxicity. 11 Micafungin, recently approved in Japan and USA, is a new echinocandin lipopeptide synthesized through the chemical modification of a fermentation product from Coleophoma empetri. 12 In vitro, the minimum concentration of micafungin required to inhibit the growth of 90% of isolates (MIC 90 ) for yeast-like organisms was lower than that for fluconazole, itraconazole or amphotericin B. 13 Preclinical studies have shown micafungin to have a broad spectrum of activity against Candida and Aspergillus species. [14] [15] [16] Micafungin has been assessed in HIV-positive patients with oesophageal candidiasis and was well tolerated at fixed daily doses of 50, 100 and 150 mg, with daily doses of 100 and 150 mg being more effective than 50 mg. 17 An earlier study of micafungin in neutropaenic patients demonstrated that doses up to 200 mg/day (equivalent to a dose of 3 mg/kg per day in a 65 kg patient) were well tolerated. 9 The current study shows that daily doses of up to 8 mg/kg (mean dose of 600 mg) were well tolerated. The criteria for the MTD were not met in either study. The wide range of doses that are well tolerated suggests an advantage with regard to flexibility in dosing.
As all patients completed at least 8 days of therapy, this study fulfilled the minimum treatment duration for discerning any drug-related toxicity. The study protocol stated that patients should complete a minimum of 7 days of treatment. The average duration of treatment was similar across treatment groups, which is consistent with an absence of dose-related toxicity.
All the adverse events noted in the present study generally reflected complications associated with HSCT, and none showed a clear increase in incidence with increasing dose. The slightly higher incidence of adverse events, irrespective of causality to study drug, in the 6 mg/ kg/group may be due to the higher proportion of allogeneic transplant recipients receiving their concomitant immunosuppressive medication but the number of patients per group is too small to draw firm conclusions. Micafungin showed minimal evidence of histamine-like reactions or systemic infusion-related reactions. Injection-site reactions including phlebitis were seldom.
Laboratory parameters for liver function were assessed in detail in the current study, and showed minimal evidence of dose-related hepatotoxicity. There was an increase in creatinine in the 6.0 mg/kg/day group (though the mean was within normal limits and not clinically significant, Table 4 ), this might be due to the higher number of allogeneic recipients who received cyclosporine as immunosuppressive therapy. However, the number of patients receiving cyclosporine in each dosage group is too low to draw any conclusion about this potential interaction with higher doses. Formal pharmacokinetic interaction studies were performed on concomitant cyclosporine and micafungin and on concomitant tacrolimus and micafungin in healthy volunteers. Cyclosporine and tacrolimus had no effect on the pharmacokinetics of micafungin (Herbert et al. 18, 19 ; data on file, Astellas). In addition micafungin had no effect on the pharmacokinetics of tacrolimus (Herbert et al. 19 ; data on file, Astellas Pharma). The study published by Herbert et al. 18 showed that micafungin appears to decrease the apparent oral clearance of a single dose of cyclosporine. However, a previously performed study revealed that co-administration of micafungin had no effect on the pharmacokinetics of steady-state cyclosporine (data on file, Astellas Pharma).
Assessment of efficacy was not a main objective of this study. However, findings on the incidence of fungal Table 4 Mean laboratory values (standard error) at baseline and end of therapy by treatment group In conclusion, the criteria for MTD was not met in our study and thus can be inferred to be 8 mg/kg/day or higher. The excellent safety profile of this novel 1,3-b-D-glucan synthetase inhibitor, and the supportive efficacy findings show promise for antifungal prophylaxis in this high-risk patient group.
